Embecta Posts 56c Adj EPS in Q3, Beating Dismal Expectations
EMBC sits 32% above its 52-week low of $2.77.
Summary
Embecta reported Q3 adjusted EPS of 56c, a significant beat against the backdrop of its disastrous Q2, where it posted a net loss and slashed guidance and the dividend by 93%. Q3 revenue was $271.7M, down 8.1% year-over-year, and adjusted operating margin was 25.5%. The company raised FY2026 adjusted EPS guidance to $1.80-$1.90 from $1.55-$1.75 and adjusted operating margin to 23.5%-24.0% from 22.25%-23.25%. The company has been under pressure from a securities class action lawsuit alleging concealed competitive threats, and its recent Owen Mumford acquisition added complexity. This earnings print suggests stabilization and may force short sellers to reconsider. Embecta sees 2026 revenue of $1.015B-$1.035B and 2026 adjusted EPS of $1.80-$1.90.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Embecta's Q3 revenue was $271.7M, down 8.1% year-over-year; adjusted operating margin was 25.5%. The company raised FY2026 adjusted EPS guidance to $1.80-$1.90 from $1.55-$1.75 and adjusted operating margin to 23.5%-24.0% from 22.25%-23.25%.
At the time of this announcement, EMBC was trading at $3.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $207.6M. The 52-week trading range was $2.77 to $15.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.